

A peer-reviewed version of this preprint was published in PeerJ on 13 January 2015.

[View the peer-reviewed version](https://doi.org/10.7717/peerj.725) (peerj.com/articles/725), which is the preferred citable publication unless you specifically need to cite this preprint.

Vlachakis D, Fakourelis P, Megalooikonomou V, Makris C, Kossida S. 2015. DrugOn: a fully integrated pharmacophore modeling and structure optimization toolkit. PeerJ 3:e725
<https://doi.org/10.7717/peerj.725>

DrugOn: a fully integrated pharmacophore modeling and structure optimization toolkit

Dimitrios Vlachakis, Paraskevas Fakourelis, Christos Makris, Sophia Kossida

During the past years pharmacophore modeling has become one of the key components in computer-aided drug design and generally in modern drug discovery. DrugOn is a fully interactive pipeline designed to exploit the advantages of modern programming and overcome the command line barrier with two friendly environments for the user (either novice or experienced in the field of Computer Aided Drug Design) to perform pharmacophore modeling through an efficient combination of the PharmACOphore, Gromacs, Ligbuilder and PDB2PQR suites. Our platform features a novel workflow that guides the user through each logical step of the iterative 3D structural optimization setup and drug design process. For the pharmacophore modeling we are focusing on either the characteristics of the receptor or the full molecular system, including a set of selected ligands. DrugOn can be freely downloaded from our dedicated server system at www.bioacademy.gr/bioinformatics/drugon/

DrugOn: a fully integrated pharmacophore modeling and structure optimization toolkit

Dimitrios Vlachakis^{1,2,#,*}, Paraskevas Fakourelis^{1,2,#}, Christos Makris² and Sophia Kossida^{1,3*}

¹ Bioinformatics & Medical Informatics Team, Biomedical Research Foundation, Academy of Athens, Athens, Greece,

² Computer Engineering and Informatics Department, University of Patras, Patras, Greece.

³ IMGT, Laboratoire d'ImmunoGénétique Moléculaire, Institut de Génétique Humaine, Montpellier, France.

Equally contributing authors

* Corresponding authors: dvlachakis@bioacademy.gr, skossida@bioacademy.gr

ABSTRACT

During the past years pharmacophore modeling has become one of the key components in computer-aided drug design and generally in modern drug discovery. DrugOn is a fully interactive pipeline designed to exploit the advantages of modern programming and overcome the command line barrier with two friendly environments for the user (either novice or experienced in the field of Computer Aided Drug Design) to perform pharmacophore modeling through an efficient combination of the PharmACOphe, Gromacs, Ligbuilder and PDB2PQR suites. Our platform features a novel workflow that guides the user through each logical step of the iterative 3D structural optimization setup and drug design process. For the pharmacophore modeling we are focusing on either the characteristics of the receptor or the full molecular system, including a set of selected ligands. DrugOn can be freely downloaded from our dedicated server system at www.bioacademy.gr/bioinformatics/drugon/

INTRODUCTION

Fully automated methods of pharmacophore model design can help facilitate the process of modern computer based drug discovery ([Chen et al. 2013](#); [Wallach & Lilien 2009](#)). Computers gain credibility in the field of computational biology and drug design, as new more efficient algorithms and pipelines are established ([Donsky & Wolfson 2011](#); [Loukatou et al. 2014](#); [Ortuso et al. 2006](#)).

The idea of pharmacophore was first defined by Paul Ehrlich as 'a molecular framework that carries (phoros) the essential features responsible for a drug's (pharmacon) biological activity' back in 1909 ([Ehrlich 1909](#); [Guner 2000](#)). According to the recent definition by IUPAC, a pharmacophore model is 'an ensemble of steric and electronic features that is necessary to ensure the

optimal supramolecular interactions with a specific biological target and to trigger or block its biological response ([Wermuth 1998](#)).

With computer-aided drug design being an integral part of the drug discovery and lead optimization process, pharmacophore models have become a key component in understanding the receptor-ligand interactions. Specifically, pharmacophore models have contributed in evolving the drug design process by shifting the focus from 2-dimensional atoms connectivity to 3-dimensional chemical features arrangement ([Faulon et al. 2008](#); [Guner 2002](#); Balatsos et al. 2012; Dalkas et al. 2013) where the features might be hydrophobic or hydrophilic regions, specific atoms, centers of aromatic or not aromatic rings, positive or negative charges and hydrogen bond donors or acceptors ([Pires et al. 2014](#); [Zhang et al. 2005](#)). The 3D pharmacophore modeling methods take into consideration the 3-dimensional structures and binding of receptors and inhibitors, in order to identify areas that are favorable or unfavorable to a specific receptor-inhibitor interaction ([Vlachakis et al. 2012b](#); [Vlachakis & Kossida 2013](#)). Pharmacophore models contribute to drug discovery by providing a number of benefits, such as the fact that they represent chemical function, valid for the existing bounds as well as for unknown agents. In addition, they are computationally efficient due to their simplicity, which makes them suitable for large scale high throughput virtual screening ([Floris et al. 2011](#); [Frommel et al. 2003](#); [Vlachakis et al. 2013a](#); [Vlachakis et al. 2013b](#)). Finally they are comprehensive and editable, so the information can be easily traced back by adding or omitting chemical feature constraints. A pharmacophore model can be expressed in two ways, firstly in a ligand-based approach and secondly in a structure-based approach ([Yang 2010](#)). A major goal in drug design is to increase potency by optimizing interactions such as the binding of a ligand to its pharmacological target, that requires complementarity of both bonding partners in terms of shape and electrostatics ([Korb et al. 2010](#)). Pharmacophore models have been already used in a variety of projects in order to exploit their benefits in high throughput virtual screening ([Fei et al. 2013](#); [Niu et al. 2013](#); [Suresh & Vasanthi 2010](#); [Vlachakis et al. 2013c](#); [Vlachakis et al. 2014](#)). Pharmacophore models have been successfully used for the identification of human chymase inhibitors ([Arooj et al. 2013](#)) and for the efficient overlay of drug-like organic molecules ([Wolber et al. 2006](#)). The benefits of pharmacophore modeling at computer-aided drug design resulted in the development of a variety of automated tools and applications during the past 20 years ([Vlachakis et al. 2013d](#); [Vlachakis et al. 2013e](#); [Vlachakis et al. 2013g](#)). However the pharmacophore modeling approaches have not reached yet their full potential, as they are limited by a number of obstacles, which are dictated by the ongoing demand for reducing today's very high cost of drug design and drug discovery ([Yang 2010](#); [Vlachakis et al. 2013h](#); [Vlachakis et al. 2013i](#)).

Herein, we introduce DrugOn, a free, open source, unix-based software package for pharmacophore modeling. DrugOn is an interactive platform combining the algorithms of PDB2PQR v.1.8 ([Dolinsky et al. 2007](#); [Dolinsky et al. 2004](#)), Ligbuilder v.1.2 and v.2.0 ([Wang et al. 2000](#); [Yuan et al. 2011](#)), Gromacs v.4.5.5 ([Prunk et al. 2013](#)) and pharmACophore ([Korb et al. 2010](#)) in

a seamless rational pipeline developed in Perl/Tcl-Tk. All previously mentioned suites remain a set of numerous modules, lacking an object-oriented graphical user interface (GUI) to facilitate their use. DrugOn was developed to smoothen and automate the tedious tasks of pharmacophore modeling and 3D structure optimization. In order to provide the user with a 3D molecular viewer, whose usage is a focal point in modern drug discovery and in computer-aided drug design, we also incorporated the Pymol suite (DeLano 2002). The DrugOn idea is to provide a scientifically sound pharmacophore design suite, which remains easy to comprehend and work with. As a result DrugOn's audience includes both the inexperienced, novice student to the highly demanding researcher and expert in the field of computer-aided drug design. So, by developing a basic interface for novice users we provide them with an automated platform that will enable them to learn by making easy experiments and to practice in computer-aided drug design by utilizing their ideas and overcoming their lack of experience. On the other hand DrugOn Pro has a fully integrated interface with all the parameterization an expert needs. More specifically DrugOn addresses all common problems associated with PDB file formatting and partial charges. Subsequently, the receptor is structurally optimized by energy minimization using a variety of different force fields as implemented into Gromacs. After structural optimization, the Ligbuilder suite is used to generate novel molecules for the given site or to improve an existing family lead or set of compounds. Finally, the pharmACOphore program is used for the pairing of ligands, resulting in the construction of a 3D pharmacophore model.

PIPELINE'S METHODS AND DESCRIPTION

With a universal installation procedure the DrugOn suite provides the user with two interfaces to choose from. DrugOn Pro is intended for more experienced users while the basic, abstract version of DrugOn is intended for inexperienced novice users. A comprehensive flowchart of the DrugOn pipeline can be found in Figure S1.

DrugOn

In the main window of DrugOn, the tab layout changes into a frame layout at the left of the main window with two buttons "next" and "previous" (Fig. 1) in order to make the step-by-step process more efficient and the layout smoother for the novice users. It also provides the user with a process log window, at the right of the main window for the real time calculations that take place in the background, with one vertical and one horizontal scroll bars, thus making the information that the user provided easier to traced back. In the DrugOn pipeline, the process for a pharmacophore modeling experiment is broken down to four steps:

(1) Input preparation.

This is the first and very essential step, which is missing from a lot of major suites, where the input (PDB) files are automatically checked and repaired so that all compatibility issues are addressed and basic chemical information is calculated before the experiment. In addition, the missing

hydrogens are added and partial charges are calculated.

However, in order to make the process easier for the novice users, the choices to remove heteroatoms, for the force field, and to neutralize or not the C' and N' termini of the protein have been selected by default. Therefore, the responsibility of the user is only to choose the input PDB file, as well as the name and the path of the output PDB file. The above options are processed with the PDB2PQR ([Dolinsky et al. 2007](#); [Dolinsky et al. 2004](#)) algorithm.

(2) Receptor optimization.

A major problem when removing heteratoms or ligands (Input preparation) from PDB files is that the receptor structure remains in its bound conformation, unless it is structurally optimized. In this second automated step the user can benefit from the conformational optimization of the receptor. An issue that is a major drawback of many structure-based drug designing algorithms. Many inconsistencies and free energy issues that may result from the removal of heteratoms, without bringing it back to the relaxed conformation of the PDB receptor file are addressed. So by using the versatile Gromacs ([Pronk et al. 2013](#)) suite, the receptor is conformationally optimized via energy minimization before the experiment. Also in this step, the available choices for the user are the input PDB file, the name and the path of the output PDB file.

(3) Ligand building.

At this stage, the actual structure-based drug design of the new ligand structures takes place. This step enables the user to fully parameterize the ligand-building process, with the use of Ligbuilder v.1.2 ([Wang et al. 2000](#)). The user has just to define the active or pocket of interest by positioning a 'seed' chemical structure in it. Then the algorithm will proceed with either the growing of the seed to a drug-like compound, using the predefined criteria in the parameters window or the linking approach (for multiple seeds). Finally the drug candidates that do not comply with the user's criteria will be screened out, by applying a similarity cutoff filter, that is user configurable.

(4) Pharmacophore.

The final step of the DrugOn pipeline is the automatic structure alignment of the molecules that were produced in the previous steps. At this point, the similarity-based scoring function tuned for ligand-based pose prediction is combined with a hybrid ant colony optimization algorithm via pharmACOPHORE ([Korb et al. 2010](#)). The scoring function combines an intraligand potential with the distance-dependent potential. The description of molecular similarity is based on hydrogen bond donors and acceptors as well as ring systems and other pharmacophoric features. The identification of corresponding pharmacophoric features in this method depends on the accuracy of the scoring function. Therefore, a fully parameterized configuration file has been created in order to serve the pharmacophore modeling experiments.

179 Toolkits description

180 Furthermore, in DrugOn's interface, a manual for the use of DrugOn is
181 provided using the system's default web browser through the help button.
182 Options such as print, clear, save and load all output files are provided to the
183 user in order to print or save for further analysis, trace errors, as well as load
184 previous experiments. Finally there is an option to clear the output of the log
185 process window in order to start a completely new experiment without any
186 trace of previous outputs that have no longer any use and might be
187 confusing and time-consuming for the user to manually edit. All those options
188 that were introduced earlier have keyboard shortcuts that can be found at
189 the File button on the window's top left corner, for faster and more ergonomic
190 use. Additionally, a button for opening a new terminal is available in case the
191 user needs two or more terminals for other uses (besides DrugOn) when an
192 experiment takes place, as the terminal from which the DrugOn was launched
193 is occupied until the user exits DrugOn. With the handle databases button the
194 user can view and edit molecule databases from the window that pops up.
195 The format that is supported is based on the one used by Ligbuilder to
196 manage fragment and molecular databases. Every database is a folder
197 consisting of the included molecule files in .mol2 format and an INDEX text
198 file which lists the molecular parameters alongside extra information and
199 properties bound to each molecular entry. Also there is a preferences button,
200 through which the user can handle some of the DrugOn settings, like module
201 path settings and the system's local folder management. By default the
202 software paths and installation sites are user defined at the DrugOn
203 automated setup. Another frame in the preferences window contains the
204 default parameter files, where the user can set the default parameter file
205 that will be used for any given experiments. These files are stored/saved and
206 can be re-used as recipe files to re-run similar experiments by just altering
207 the input files. Moreover, an experiment preparation log is saved in the form
208 of a lab-book with the experimental parameters that are of importance to
209 pharmacophore design, next to a recording of the input files, the date and
210 the computer used to run the simulation. This way, troubleshooting becomes
211 easy when things go wrong and the chances of finding what went wrong
212 increase dramatically. Moreover in the preferences window the user has the
213 option to choose the preferred applications, for the text editor, terminal
214 molecular viewer and xvg graph viewer. Additionally, DrugOn's pipeline is
215 capable of starting a log file from the preferences menu where the user
216 predefines. DrugOn will automatically save all output results from the
217 experiments that take place in the form of plain text file format for future
218 reference. This option is essential for keeping track of all useful information
219 that is complicated and takes a lot of time for some users. These files are
220 pre-formatted and ready to print, email or convert into PDF format. Notably,
221 the status tray area provides the user with 2 progress indicators, a progress
222 bar and a percentage (%) of the completed work. A processor's, memory and
223 swap file usage gauge is to be found right next to the logging indicator,
224 providing real time information of systems resources.

225 DrugOn Pro

226 DrugOn Pro is a more comprehensive, in depth approach aimed to the more
227 expert and professional users. DrugOn's Pro main window is a menu interface
228 with a tab step-by-step layout (Fig. 2). It also provides the user with a process
229 log window, at the bottom of the main window for the real time calculations
230 that take place in the background, with one vertical and one horizontal scroll
231 in order to make the information that the user provided easily traced back.
232 At the DrugOn Pro interface for a pharmacophore modeling experiment the
233 process is separated in the four same steps as DrugOn with some difference
234 most likely in parameterization:

235 (1) *Input preparation.*

236 Where the user has the benefit to fully parameterize the pdb input file
237 with choices such as: removing heteroatoms, choosing the force field, and
238 choosing whether to neutralize or not the C' and N' termini of the protein.
239 The above options are processed with the PDB2PQR ([Dolinsky et al. 2007](#);
240 [Dolinsky et al. 2004](#)) algorithm.

241 (2) *Receptor optimization.*

242 The second step of DrugOn Pro remains the same with DrugOn only that
243 here the user has the choice to either use the default parameters or fully
244 customize the parameters for the experiment. The parameters in this step
245 are: the force field that Gromacs uses (Force Field), the type of periodic
246 box that surrounds the protein (Box Type), the distance parameter that
247 decides the size of the box where dynamics will take place (Sol-Box
248 Distance), the choice to perform energy minimization in the presence or
249 absence of water (Solvate Protein in Water), the water model that is used
250 for water molecules (Water Model), the option to remove the overall
251 charge from the system (Neutralize system), the option to remove or leave
252 the water or ions in the output PDB File (Remove water/ions from output
253 PDB File), the option to show a graph of the protein's potential energy
254 MDRun (Show resulting Energy Graph) and to path the parameter file
255 needed for energy minimization (Parameter File) available for the user.

256 (3) *Build ligands.*

257 At this stage, the actual structure-based drug design of the new ligand
258 structures takes place. DrugOn Pro enables the user to fully parameterize
259 the ligand-building process, with the use of not only Ligbuilder v.1.2 but
260 also Ligbuilder v.2.0 ([Wang et al. 2000](#); [Yuan et al. 2011](#)).

261 • Ligbuilder v.1.2:

262 The use of Ligbuilder v.1.2 stays the same as DrugOn, So the user still
263 has the options of pocket, grow, link and process but also has the
264 option of Ligbuilder v.2.0.

265 • Ligbuilder v.2.0:

266 When using Ligbuilder 2.0 the cavity is automatically detected. In the
267 case of many potential active sites the user will be asked to choose

one. The parameters set in the Parameter and Index files are used to start the drug design process. So at this step the process is organized in three fully user-customizable phases. First it prepares and summarizes the 3D properties of the scaffolding, common core structures that later will be generated and analyzed. Then the user has to choose between the growing and linking algorithms of Ligbuilder, as soon as the user has completed the parameters setup section and then the combination of molecular fragments starts automatically. Finally the elite molecules are selected for the next step, in the compound screening function.

(4) Pharmacophore.

At the final step, because the identification of corresponding pharmacophoric features in pharmACOPhore method counts on the accuracy of the scoring function the DrugOn Pro benefits the users pharmacophore modeling experiments with two more options. So, the user has the choice of a fully parameterized configuration file that pharmACOPhore uses (the default that DrugOn). Moreover the user is provided with the option to create/edit his own configuration file with the parameters that are needed for each experiment.

A major issue with most major drug design/pharmacophore suites is the installation process on UNIX/Linux based systems, as the command line is not very popular to the majority of the pc users. That is especially true for people that use only graphically enabled operating systems and avoid using every application or software package that runs on linux because of its difficulty when graphical interface is not an option. The DrugOn is a pipelined software package based on Linux-ubuntu systems, that has been specifically designed to provide the user with a seamless setup via a graphical interface that simplifies the installation of DrugOn.

VALIDATION

DrugOn is not the first platform designed for pharmacophore modeling. A similar pipeline approach for a complete drug design toolkit (not pharmacophore) has been published by ([Vlachakis et al. 2013f](#)) with the Drugster toolkit. Moreover, a series of different approaches have been made the past years which resulted in some commercially available suits like MOE ([MOE 2010](#)), or some free available suits like pharmer ([Koes & Camacho 2011](#)) and open3dqsar ([Tosco & Balle 2011](#)), two really good and efficient software packages that have been developed. Schrödinger has also developed Phase, which is also distributed as a commercial module of the Maestro suite (Dixon et al. 2006a; Dixon et al. 2006b).

In an effort to quantitatively and qualitatively evaluate the performance of DrugOn we used two different and quite diverge use cases. First use case was the crystal structure of the chimeric protein of 5-HT1B-BRIL, pdb entry: 4IAR

310 (Figure S2) and secondly the case of the pharmacophore design for PARN
311 (Figure S3) (Vlachakis et al. 2012a). As benchmark control we compared
312 DrugOn firstly to the rather expensive and commercially available package
313 MOE and its build-in modules (breed) and secondly to the Schrödinger suite
314 and its built-in pharmacophore module named Phase. The results have been
315 summarized in figures S2 and S3. It is clear that in both cases the DrugOn
316 suite performed as good as the other rather expensive rival commercial
317 suites. The number, structure and 3D alignment of candidate compounds and
318 3D pharmacophore model design as it was produced by DrugOn is almost
319 identical to that of MOE and similar to Phase. As far as accuracy and
320 reliability goes, we are now confident that DrugOn reported a set of
321 pharmacophore models that has been evaluated and confirmed by *in vitro*
322 assays, as the predicted poly-A-DNP was found active in the sub-milimolar
323 range (Vlachakis et al. 2012a)

324 CONCLUSION

325 The DrugOn has been developed with the aim to pipeline some of the major
326 drug design suites in an effort to create reliable 3D pharmacophore models. It
327 stands out from its competition as it seamlessly combines the results of state
328 of the art algorithms and suites, which are just difficult to combine and install
329 or run individually, whilst remaining distributed as freeware. Operation
330 manuals, tutorials on various use cases, quick guides for teaching purposes
331 as well as multimedia/video installation guidelines and scientific support for
332 DrugOn is provided via our dedicated webserver at:
333 <http://www.bioacademy.gr/bioinformatics/drugon/>.

334 Figure Legends:

335 **Figure 1.** The main window of the DrugOn platform.

336 **Figure 2.** The main window of the DrugOn Pro platform.

337 **Figure S1.** A flowchart of the DrugOn pipeline.

338 **Figure S2.** The 5-HT_{1B}-BRIL use case benchmark of DrugOn. Here is the 3D
339 alignment of the qualifying molecules for the given receptor. A) The MOE
340 result, B) The Schrödinger result and C) the DrugOn result.

341 **Figure S3.** The PARN use case benchmark of DrugOn. Top: The 3D alignment
342 of the qualifying molecules for the catalytic site of PARN. On the left is the
343 MOE output while on the right is the DrugOn result. Bottom: The final 3D
344 pharmacophore model for PARN. The MOE output is on the Left while the

DrugOn 3D pharmacophore is on the right. The results are almost identical and have been confirmed *in vitro* by enzymatic biological assays.

REFERENCES:

- Arooj M, Sakkiah S, Kim S, Arulalapperumal V, and Lee KW. 2013. A combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitors. *PLoS One* 8:e63030.
- Balatsos N, Vlachakis D, Chatzigeorgiou V, Manta S, Komiotis D, Vlassi M, Stathopoulos C. 2012 Kinetic and *in silico* analysis of the slow-binding inhibition of human poly (A)-specific ribonuclease (PARN) by novel nucleoside analogues. *Biochimie* 94 (1), 214-221
- Chen M, Svicher V, Artese A, Costa G, Alteri C, Ortuso F, Parrotta L, Liu Y, Liu C, Perno CF, Alcaro S, and Zhang J. 2013. Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage. *Bioinformatics* 29:451-460.
- Dalkas GA, Vlachakis D, Tsagkrasoulis D, Kastania A, and Kossida S. 2013. State-of-the-art technology in modern computer-aided drug design. *Brief Bioinform* 14:745-752.
- DeLano WL. 2002. The PyMOL Molecular Graphics System DeLano Scientific. San Carlos, CA, USA.
- Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. 2006a "PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model Development, and 3D Database Screening. 1. Methodology and Preliminary Results," *J. Comput. Aided Mol. Des.* 20, 647-671
- Dixon, S.L.; Smondyrev, A.M.; Rao, S.N. 2006b "PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching," *Chem. Biol. Drug Des.* 67, 370-372
- Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, and Baker NA. 2007. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. *Nucleic Acids Res* 35:W522-525.
- Dolinsky TJ, Nielsen JE, McCammon JA, and Baker NA. 2004. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. *Nucleic Acids Res* 32:W665-667.
- Donsky E, and Wolfson HJ. 2011. PepCrawler: a fast RRT-based algorithm for high-resolution refinement and binding affinity estimation of peptide inhibitors. *Bioinformatics* 27:2836-2842.
- Ehrlich P. 1909. Ueber den jetzigen Stand der Chemotherapie. *Ber Dtsch Chem Ges* 42:17-47.
- Faulon JL, Misra M, Martin S, Sale K, and Sapra R. 2008. Genome scale enzyme-metabolite and drug-target interaction predictions using the signature molecular descriptor. *Bioinformatics* 24:225-233.
- Fei J, Zhou L, Liu T, and Tang XY. 2013. Pharmacophore modeling, virtual screening, and molecular docking studies for discovery of novel Akt2 inhibitors. *Int J Med Sci* 10:265-275.
- Floris M, Masciocchi J, Fanton M, and Moro S. 2011. Swimming into peptidomimetic chemical space using pepMMsMIMIC. *Nucleic Acids Res* 39:W261-269.
- Frommel C, Gille C, Goede A, Gropl C, Hougardy S, Nierhoff T, Preissner R, and Thimm M. 2003. Accelerating screening of 3D protein data with a graph theoretical approach. *Bioinformatics* 19:2442-2447.
- Guner OF. 2000. *Pharmacophore Perception, Development, and Use in Drug Design*: Intl Univ Line; 1 edition.
- Guner OF. 2002. History and evolution of the pharmacophore concept in computer-aided drug design. *Curr Top Med Chem* 2:1321-1332.

- 397 Koes DR, and Camacho CJ. 2011. Pharmer: efficient and exact pharmacophore
398 search. *J Chem Inf Model* 51:1307-1314.
- 399 Korb O, Monecke P, Hessler G, Stutzle T, and Exner TE. 2010. pharmACOPhore:
400 multiple flexible ligand alignment based on ant colony optimization. *J Chem*
401 *Inf Model* 50:1669-1681.
- 402 Loukatou S, Papageorgiou L, Fakourelis P, Filntisi A, Polychronidou E, Bassis I,
403 Megalooikonomou V, Makalowski W, Vlachakis D, and Kossida S. 2014.
404 Molecular dynamics simulations through GPU video games technologies.
405 *Journal of Molecular Biochemistry* 3.
- 406 MOE v. 2010. C.C.G. 1010 Sherbrooke St West, Suite 910, Montreal, Canada, H3A
407 2R.
- 408 Niu M, Dong F, Tang S, Fida G, Qin J, Qiu J, Liu K, Gao W, and Gu Y. 2013.
409 Pharmacophore modeling and virtual screening for the discovery of new type
410 4 cAMP phosphodiesterase (PDE4) inhibitors. *PLoS One* 8:e82360.
- 411 Ortuso F, Langer T, and Alcaro S. 2006. GBPM: GRID-based pharmacophore model:
412 concept and application studies to protein-protein recognition. *Bioinformatics*
413 22:1449-1455.
- 414 Pires DE, Ascher DB, and Blundell TL. 2014. mCSM: predicting the effects of
415 mutations in proteins using graph-based signatures. *Bioinformatics* 30:335-
416 342.
- 417 Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC,
418 Kasson PM, van der Spoel D, Hess B, and Lindahl E. 2013. GROMACS 4.5: a
419 high-throughput and highly parallel open source molecular simulation toolkit.
420 *Bioinformatics* 29:845-854.
- 421 Suresh N, and Vasanthi NS. 2010. Pharmacophore Modeling and Virtual Screening
422 Studies to Design Potential Protein Tyrosine Phosphatase 1B Inhibitors as New
423 Leads. *Journal of Proteomics & Bioinformatics* 3:20-28.
- 424 Tosco P, and Balle T. 2011. Open3DQSAR: a new open-source software aimed at
425 high-throughput chemometric analysis of molecular interaction fields. *J Mol*
426 *Model* 17:201-208.
- 427 Vlachakis D, Argiro A, and Kossida S. 2013a. An update on virology and emerging
428 viral epidemics. *Journal Molecular Biochemistry* 2:80-84.
- 429 Vlachakis D, Bencurova E, Papangelopoulos N, and Kossida S. 2014. Current State-of-
430 the-Art Molecular Dynamics Methods and Applications. *Adv Protein Chem*
431 *Struct Biol* 94:269-313.
- 432 Vlachakis D, Karozou A, and Kossida S. 2013b. 3D Molecular Modelling Study of the
433 H7N9 RNA-Dependent RNA Polymerase as an Emerging Pharmacological
434 Target. *Influenza Res Treat* 2013:645348.
- 435 Vlachakis D, Kontopoulos DG, and Kossida S. 2013c. Space constrained homology
436 modelling: the paradigm of the RNA-dependent RNA polymerase of dengue
437 (type II) virus. *Comput Math Methods Med* 2013:108910.
- 438 Vlachakis D, Koumandou VL, and Kossida S. 2013d. A holistic evolutionary and
439 structural study of flaviviridae provides insights into the function and
440 inhibition of HCV helicase. *PeerJ* 1:e74.
- 441 Vlachakis D, and Kossida S. 2013e. Molecular modeling and pharmacophore
442 elucidation study of the Classical Swine Fever virus helicase as a promising
443 pharmacological target. *PeerJ* 1:e85.
- 444 Vlachakis D, Pavlopoulou A, Tsiliki G, Komiotis D, Stathopoulos C, Balatsos NA, and
445 Kossida S. 2012a. An integrated in silico approach to design specific inhibitors
446 targeting human poly(a)-specific ribonuclease. *PLoS One* 7:e51113.
- 447 Vlachakis D, Tsagrasoulis D, Megalooikonomou V, and Kossida S. 2013f. Introducing
448 Drugster: a comprehensive and fully integrated drug design, lead and
449 structure optimization toolkit. *Bioinformatics* 29:126-128.
- 450 Vlachakis D, Tsaniras SC, Feidakis C, and Kossida S. 2013g. Molecular modelling
451 study of the 3D structure of the biglycan core protein, using homology
452 modelling techniques. *Journal Molecular Biochemistry* 2:85-93.

- 453 Vlachakis D, Tsaniras SC, and Kossida S. 2012b. Current viral infections and
454 epidemics of flaviviridae; lots of grief but also some hope. *Journal Molecular*
455 *Biochemistry* 3.
- 456 Vlachakis D, Tsiliki G, and Kossida S. 2013h 3D Molecular Modelling of the Helicase
457 Enzyme of the Endemic, Zoonotic Greek Goat Encephalitis Virus. *Springer*
458 383:165-171.
- 459 Vlachakis D, Tsiliki G, Pavlopoulou A, Roubelakis MG, Tsaniras SC, and Kossida S.
460 2013i. Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi)
461 Technology. *Evol Bioinform Online* 9:203-213.
- 462 Wallach I, and Lilien RH. 2009. Prediction of sub-cavity binding preferences using an
463 adaptive physicochemical structure representation. *Bioinformatics* 25:i296-
464 304.
- 465 Wang R, Gao Y, and Lal L. 2000. LigBuilder: a multi-purpose program for structure-
466 based drug design. *Journal of Molecular Modeling* 6:498-516.
- 467 Wermuth CG. 1998. Glossary of terms used in medicinal chemistry (IUPAC
468 recommendations 1997). *Annu Rep Med Chem* 33:385-395.
- 469 Wolber G, Dornhofer AA, and Langer T. 2006. Efficient overlay of small organic
470 molecules using 3D pharmacophores. *J Comput Aided Mol Des* 20:773-788.
- 471 Yang SY. 2010. Pharmacophore modeling and applications in drug discovery:
472 challenges and recent advances. *Drug Discov Today* 15:444-450.
- 473 Yuan Y, Pei J, and Lai L. 2011. LigBuilder 2: a practical de novo drug design
474 approach. *J Chem Inf Model* 51:1083-1091.
- 475 Zhang M, White RA, Wang L, Goldman R, Kavraki L, and Hassett B. 2005. Improving
476 conformational searches by geometric screening. *Bioinformatics* 21:624-630.

1

Figure 1

The main window of the DrugOn platform.




Figure 2

The main window of the DrugOn Pro platform.

